
Biocon Limited has informed the Exchange regarding a press release dated December 13, 2025, titled "Biocon Biologics Signs Settlement and License Agreement to Commercialize Biosimilar Aflibercept Worldwide".
Filed with NSE · · 3 pages · English
Biocon Limited has issued a press release announcing a settlement and license agreement for the commercialization of biosimilar Aflibercept worldwide. This agreement allows Biocon Biologics to launch Yesafili®, a biosimilar Aflibercept, in various countries, following previous settlements in the U.S. and Canada. Biocon Biologics aims to enhance access to this treatment for patients with various ophthalmology conditions.
Written by 6ix AI from the company’s filing. How 6ix writes summaries

Biocon Limited has informed the Exchange regarding a press release dated December 13, 2025, titled "Biocon Biologics Signs Settlement and License Agreement to Commercialize Biosimilar Aflibercept Worldwide".
Follow Biocon into a list and get an email when it puts out news.
Follow Biocon